Grail's CEO, Hans Bishop, resigned after the clinical trial failed. The tests showed that their Galleri cancer screening test did not achieve the expected results. Grail has announced leadership changes in response to this setback. The article also mentions Epstein's friend's return to biotechnology. It also reports on Prasad's departure from the FDA, described as a "part deux". These events are part of the news from the biotech sector in The Readout podcast.